IRVING, Texas, Aug. 28,
2013 /PRNewswire/ -- RBC Life Sciences, Inc. (OTCQB: RBCLD), a
provider of proprietary nutritional supplements, and wound care and
pain management products (the "Company"), today announced that its
Board of Directors approved a share repurchase program, authorizing
the Company to repurchase in the aggregate up to 111,000 shares,
representing 5% of the shares, of its currently outstanding common
stock.
"This is part of our strategy to deliver value to our
shareholders" said Clinton H.
Howard, the Company's Chairman and Chief Executive
Officer. "We view a share repurchase program as an
opportunity to enhance the intrinsic value of RBC Life
Sciences."
Under the share repurchase program, which expires on
February 28, 2015, the Company may
repurchase its shares in open-market purchases or through privately
negotiated transactions. The decision to effect, and the timing and
amount of, such share repurchases will depend upon market
conditions, the Company's cash position and other corporate
considerations, including applicable securities laws. The
share repurchases will be funded from the Company's existing cash
resources. There is no guarantee as to the number of shares
that the Company may repurchase.
The Company's share repurchase program may be amended,
supplemented or suspended at any time and for any reason,
including, without limitation, market conditions, the cost of
repurchasing shares, the availability of alternative investment
opportunities, liquidity and other factors deemed appropriate by
the Company's Board of Directors, subject to applicable securities
laws.
In connection with the share repurchase program, the Company may
adopt one or more plans pursuant to the provisions of Rule 10b5-1
under the Securities Exchange Act of 1934, as amended.
About RBC Life Sciences
Through wholly owned subsidiaries, RBC Life Sciences, Inc.
develops, manufactures and markets high-quality nutritional
supplements under the RBC Life brand to a growing population of
consumers seeking a healthy lifestyle and an opportunity to
increase their long-term family income. Through its wholly owned
subsidiary, MPM Medical, the Company also develops and markets to
health care professionals in the United
States proprietary prescription and nonprescription products
for advanced wound care and pain management. All products are
tested for quality assurance in-house, and by outside independent
laboratories, to comply with regulations in the United States and in more than thirty
countries in which the products are distributed. For more
information, visit the Company's website at
www.rbclifesciences.com.
The statements above, other than statements of historical
fact, that express a belief, expectation, projection or intention
may be forward-looking statements within the meaning of the federal
securities laws. Forward-looking statements may contain the
words "expect," "intend," "plan," "anticipate," "estimate,"
"believe," "will be," "will continue," "will likely result" and
similar expressions, or future conditional verbs such as "may,"
"will," "should," "would" and "could." Actual events will be
dependent upon a number of factors and risks, including, but not
limited to, changes in plans by the Company's management, delays or
problems in production, changes in the regulatory process, changes
in market trends and a number of other factors and risks described
from time to time in the Company's filings with the Securities and
Exchange Commission. Although we believe that the
expectations reflected in these forward-looking statements are
reasonable, we can give no assurance that such expectations will
prove to have been correct. Further, we specifically disclaim
any duty to update any of the information set forth in this press
release, including any forward-looking statements.
Forward-looking statements are made based on management's current
expectations and beliefs concerning future events and, therefore,
involve a number of assumptions, risks and uncertainties.
Management cautions that forward-looking statements are not
guarantees, and our actual results could differ materially from
those expressed or implied in the forward-looking
statements.
For Further Information:
Richard S. Jablonski, VP - Finance
and CFO
Tel: 972-893-4000
rick.jablonski@rbclifesciences.com
SOURCE RBC Life Sciences, Inc.